Valid Insight

Valid Insight is an award winning specialist global market access consultancy firm. Our team are experts in understanding the global payer environment and can help you overcome the evolving market access challenges at any stage in the product lifecycle.

From determining the right strategy for you to stay competitive in your market, to helping you create a compelling and powerful value proposition, to empowering you with the latest marketplace tools and assisting you in developing your current team to help them realise their full potential, Valid Insight can be your trusted partner, and so much more.

• Value Insight and Strategy
• Evidence Development
• Marketplace Tools
• Building and Supporting Centres of Excellence
• YOUR MARKET ACCESS TEAM
• TRAVELLESS
• Pricing and Market Access Simulator

Webinar: How to price a pharmaceutical product during a global economic recession

How can you ensure your product achieves optimal market access during a global economic recession?

Using TRAVELLESS™ to provide tailored pharmaceutical training

In May 2020, Valid Insight were scheduled to travel to Grenoble to deliver the market access modules as part of the Advanced Master’s in Biotechnology & Pharmaceutical Management programme with Grenoble Ecole de Management, a French graduate business school. The course has participants from varied backgrounds, but all from roles within the pharmaceutical industry.

Homeworking: The positives and tips from the experience of the Valid Insight Team

At Valid Insight, we have had a homeworking model since our inception; a model designed to enable us to attract and recruit experienced professionals from many geographies, without the need to uproot family, travel regularly or experience long commutes. Therefore, we have extensive experience in dealing with some of the challenges, but also understand the opportunities that homeworking can bring.

Valid Insight to contribute to Advanced Master’s in Biotechnology & Pharmaceutical Management programme

At Valid Insight, we’re pleased to announce that in May 2020, we’ll be providing a series of specialist Market Access lectures as part of the Advanced Master’s in Biotechnology & Pharmaceutical Management programme with Grenoble Ecole de Management, a leading French graduate business school.

Speakers Announced: Maintaining Market Access Continuity through a Global Pandemic Webinar

The global outbreak of coronavirus (COVID-19) and subsequent perception of public health risk creates challenges for international business continuity and market access planning.

Valid Insight Supporting Initiatives To Support COVID-19 Travel Bans

The World Pharma Pricing Market Access & Evidence Congress

Come meet Valid Insight at booth C2-006 at ISPOR Europe 2019

For the fourth year in succession, we are excited and proud to be exhibiting at this year’s ISPOR 22nd Annual European Congress

The Valid Insight visit to Buckingham Palace

In April, it was announced that the Valid Insight team had been awarded the Queen’s Award for Enterprise in International Trade. It was an amazing moment for us all. It was not only a testament to the team’s hard work and indisputable expertise, but to our clients’ trust in us to help them to keep advancing patient access to medicines.

Valid Insight wins the Queen’s Most Coveted Award for Enterprise

Valid Insight, a leading pharmaceutical global market access consultancy, is one of a select number of businesses to win the esteemed Queen's Award for Enterprise: International Trade.

Are biobetters a market access opportunity?

Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen.

Why are new medicinal products denied reimbursement in France?

Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative to alternative treatments for successful market access. In this blog, we summarise the reasons for negative reimbursement decisions in 2017 and discuss common pitfalls manufacturers should avoid.

The vicious circle of pharmaceutical tendering

Pharmaceutical tendering and contracting has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s. In the 1990s, international institutions such as the World Health Organisation and the World Bank endorsed tendering as the preferred procurement process for drugs.

The benefits of a expert-led market access strategy

In order to support effective decision making and deliver sustained returns in a complex, dynamic healthcare environment, pharmaceutical, biotech and medical device companies need an expert-led market access strategy that considers the changing nature of the real-life marketplace. These strategies should not only focus on achieving the commercial objectives for a product but also enable it to outperform competitors throughout the product life cycle.

How to weather the pricing competiton

In this article, global expert in life sciences pricing and all aspects of market access, Raf De Wilde, debunks this perceived contradiction and discusses specific strategies to avoid, delay or accommodate price competition to achieve long-term sustainability.

White paper for download: Excellence In payer engagement

Strategic outputs from a roundtable discussion.

White paper for download: Maintaining market access continuity through a global pandemic

In a Valid Insight webinar, we brought together key stakeholders to discuss the global coronavirus (COVID-19) pandemic and its effects on pharmaceutical pricing and market access.

Enabling market access through outcomes-based pricing

Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines.

The growing clinical importance of patient-reported outcomes (PROs)

Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the evaluation of health and healthcare interventions.

Pricing and Market Access Simulator

Reliable tool for value assessment of pipeline products

Virtual workshops to elevate value, pricing and market access strategies

This blog post explores how well-facilitated virtual workshops can be just as valuable as face-to-face meetings.

Putting people and the planet first in 2020

Valid Insight go paperless to promote environmental sustainability within the pharmaceutical industry

The balancing act that’s keeping pharma and biotech market access on its toes

Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to get a return on investment.  What are the implications for pharma and biotech market access?

White Paper for download: Explaining the price of your product

In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step.

How do companies prepare for reimbursement?

Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement.

The 'winner takes all' pricing game

Tendering has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s. In the 1990s, international institutions such as the World Health Organisation and the World Bank endorsed tendering as the preferred procurement process for drugs.

RWE Blog 4: The place of real-world evidence in the market access strategy

The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in Real-world challenges and real-world data, understanding the payer's perspective, in Payers use real-world data cautiously, and seeing the views of both advocates and opponents of RWE in Is real-world evidence the holy grail: Finding the balance.

RWE Blog 3: Is real-world evidence the holy grail

We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use real-world data cautiously. In our third instalment, we’re looking at how to find the right balance in using RWE.

RWE Blog 2: Payers use real-world data cautiously

Following our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in our blog Real-world challenges and real-world data, the second instalment of our four-blog series looks at why payers use real-world data cautiously.

RWE Blog 1: Real-world challenges and real-world data

This is the first of a set of four blogs on real-world data (RWD) and real-world-evidence (RWE), and their role in market access.

Valid News, Market Access Insights, Issue 3

Wherever you are in the world, it’s important to have a holistic view of what’s happening in the market.

The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments

The essential medicine list (EML) contains treatments considered to be the most effective and safe in targeting global health concerns. On 9 July 2019, the World Health Organization (WHO) published the 21st edition of the EML, recommending the inclusion of 28 new medicines.

Confidential contracting – the road to flexible pricing

Excellent clinical and financial value are drivers for success in pharma, but without efficient, targeted pricing and adequate confidential contracting schemes, the success of any product is not ensured.

White paper for download: The vicious circle of pharmaceutical tendering

In this white paper, we discuss the pros of tendering, including cost reduction, but also the cons, such as supply issues and aggressive bidding consequences. Plus, our expert offers guidance on how to navigate the vicious circle.

Innovative pricing and contracting options

With rising treatment prices and healthcare spending, payer organisations are making efforts to contain costs.

White paper for download: Real-world evidence: Hurdles and the holy grail

Real-world evidence and real-world data is a hot topic in market access today. Conferences, publications and studies are all focussing on the opportunities and benefits they bring. It’s also becoming a big area of investment for pharma, biotech and life science companies.